Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.56 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.56 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23223918 | 0.96 | HTT (0.69) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL131437 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL3065465 | 0.94 | HTT (0.68) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL12409527 | 0.91 | HTT (0.80) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL2516832 | 0.91 | HTT (0.66) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL9784821 | 0.90 | HTT (0.78) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL13665317 | 0.89 | HTT (0.64) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL21559798 | 0.89 | HTT (0.72) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL5056961 | 0.88 | HTT (0.60) | HTTLMNASMN1; SMN2TGM2KEAP1 | |
| SCHEMBL7139436 | 0.88 | HTT (0.76) | HTTLMNASMN1; SMN2TGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2003103653-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6355640-B1 | TREATMENT OF HYPERTENSION, UROGENITAL DISORDERS AND FORMED BY WITTIG REACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-1150976-A1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000040578-A1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| US-5773530-A | USEFUL AS PSYCHOSTIMULANTS, ANTIHYPERTENSIVE AGENTS AND REMEDIES FOR RENAL FAILURE, DIURETICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| EP-0737193-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-16 | — | — | EP | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| WO-1995018128-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-06 | — | — | WO | disclosed |
| US-4452814-A | ANTITUMOR AGENTS | SUAMI T (JP) | 1984-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190938-A1 | NOVEL CARGO DELIVERY SYSTEM AND COMPOSITION COMPRISING THE SAME | ATG7, SQSTM1, BECN1 | HTT 156/4885LMNA 1560/4885SMN1; SMN2 1473/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | HTT 112/4885LMNA 1430/4885SMN1; SMN2 1673/4885 |
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | HTT 133/4885LMNA 2080/4885SMN1; SMN2 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.